Physician profile
Sunil Sapru
NPI 1235169558
$845.61
in general payments reported to CMS, 2019-2025
18 companies · $108 in 2025
The $108 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $57.50 · 2020: $14.16 · 2021: $47.70 · 2022: $251 · 2023: $272 · 2024: $95.74 · 2025: $108.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $475.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $475.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $136.01 | 2022-2024 | Andexxa |
| Janssen Pharmaceuticals, INC | $126.62 | 2023 | Xarelto |
| Alexion Pharmaceuticals, INC. | $91.79 | 2022-2025 | Ultomiris |
| Merck Sharp & Dohme LLC | $67.45 | 2023-2025 | Zerbaxa, Recarbrio, Dificid |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $60.14 | 2021-2025 | Xifaxan |
| Gilead Sciences, INC. | $55.51 | 2022-2024 | |
| Amgen INC. | $52.27 | 2019-2025 | Repatha, Repatha |
| Csl Behring | $33.04 | 2022 | |
| Novo Nordisk INC | $30.24 | 2019-2022 | |
| Shionogi INC | $30.22 | 2022-2025 | Fetroja |
| La Jolla Pharmaceutical Company | $29.23 | 2024-2025 | Giapreza |
| Sanofi-Aventis U.S. LLC | $27.84 | 2019 | |
| Melinta Therapeutics, LLC | $27.48 | 2022 | |
| Abbvie INC. | $19.74 | 2021 | |
| Ucb, INC. | $15.51 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Chiesi USA, INC. | $14.43 | 2022 | |
| Dynavax Technologies Corporation | $14.16 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.93 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sunil Sapru listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.